Key facts
- Tensegrity Pharma’s last known valuation is $6.1M (Jan 2025).
- It has raised $4.2M; the latest was Seed Round ($4.2M) in Jan 2025.
- Notable investors include Mitsubishi UFJ Capital, Newton BioCapital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tensegrity Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Tensegrity Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tensegrity Pharma
Developer of a new drug designed to eliminate bottlenecks and create novel value for patients. The company offers an elite, experienced team and a unique perspective on drug discovery, enabling pharmaceutical companies of all sizes to accelerate clinical development and maximize value, while revitalizing the drug discovery ecosystem.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2023
- Employees
- 10
- Website
- tensegritypharma.com/
- Ownership
- Privately Held (backing)
Tensegrity Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tensegrity Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tensegrity Pharma in its N-PORT filings yet. We sweep new filings monthly.